目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED AND REGIONS CONSIDERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary interviews
2.1.2.2 Insights from primary experts
2.1.2.3 Breakdown of primary sources
2.2 RESEARCH METHODOLOGY
2.3 MARKET SIZE ESTIMATION
2.4 DATA TRIANGULATION
2.5 MARKET RANKING ANALYSIS
2.6 RISK ASSESSMENT
2.7 STUDY ASSUMPTIONS
2.8 LIMITATIONS
2.8.1 METHODOLOGY-RELATED LIMITATIONS
2.8.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 DIGITAL HEALTH MARKET OVERVIEW
4.2 NORTH AMERICA: DIGITAL HEALTH MARKET, BY END USER AND COUNTRY
4.3 DIGITAL HEALTH MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 DIGITAL HEALTH MARKET: REGIONAL MIX
4.5 DIGITAL HEALTH MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing penetration of smartphones, tablets, and other mobile platforms
5.2.1.2 Rising geriatric population and subsequent increase in prevalence of chronic diseases
5.2.1.3 Rising focus on patient-centric healthcare solutions
5.2.1.4 Rising use of wearables
5.2.1.5 Advancements in AI, sensors, and connectivity (5G and 6G)
5.2.1.6 Growth of AI-powered virtual assistants and chatbots
5.2.2 RESTRAINTS
5.2.2.1 Low digital literacy in certain demographics
5.2.2.2 Interoperability issues
5.2.3 OPPORTUNITIES
5.2.3.1 Shift toward intelligent health ecosystem to deliver personalized health experiences
5.2.3.2 Increasing shift towards outpatient care
5.2.3.3 Improving regulatory support and reimbursements
5.2.3.4 Advancements in digital health
5.2.4 CHALLENGES
5.2.4.1 Healthcare gap in emerging economies
5.2.4.2 Privacy and security concerns
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.4 INDUSTRY TRENDS
5.4.1 EMERGENCE OF VALUE-BASED STRATEGY FOR CONTINUOUS CARE
5.4.2 HOME: NEW HEALTHCARE HUB
5.4.3 TECHNOLOGICALLY ENABLED PRIMARY CARE SERVICES
5.4.4 RISING AWARENESS OF DIGITAL THERAPEUTICS TO TREAT HUMAN DISEASES
5.4.5 SURGE IN MHEALTH APPS
5.5 ECOSYSTEM ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 TECHNOLOGY ANALYSIS
5.7.1 KEY TECHNOLOGIES
5.7.1.1 mHealth apps
5.7.1.2 Wearable sensors & devices
5.7.1.3 Remote patient monitoring
5.7.1.4 Digital therapeutics
5.7.1.5 Telehealth/virtual care platforms
5.7.1.6 AI-powered tools
5.7.2 COMPLEMENTARY TECHNOLOGIES
5.7.2.1 Cloud computing & edge processing
5.7.2.2 Data analytics & visualization
5.7.2.3 Bluetooth & IoT connectivity
5.7.2.4 EHR integration
5.7.3 ADJACENT TECHNOLOGIES
5.7.3.1 Digital twins
5.7.3.2 AR/VR & extended reality (XR)
5.7.3.3 Voice assistants/smart speakers
5.8 TARIFF AND REGULATORY ANALYSIS
5.8.1 TARIFF DATA FOR HS CODE 9018
5.8.2 TARIFF DATA FOR HS CODE 9021
5.8.3 TARIFF DATA FOR HS CODE 8517
5.8.4 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.8.5 REGULATORY FRAMEWORK
5.9 PRICING ANALYSIS
5.9.1 INDICATIVE PRICE, BY OFFERING
5.9.2 INDICATIVE PRICE, BY REGION
5.10 PORTER'S FIVE FORCES ANALYSIS
5.10.1 INTENSITY OF COMPETITIVE RIVALRY
5.10.2 BARGAINING POWER OF BUYERS
5.10.3 THREAT OF SUBSTITUTES
5.10.4 THREAT OF NEW ENTRANTS
5.10.5 BARGAINING POWER OF SUPPLIERS
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.11.2 BUYING CRITERIA
5.12 PATENT ANALYSIS
5.12.1 PATENT PUBLICATION TRENDS FOR DIGITAL HEALTH MARKET
5.12.2 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR DIGITAL HEALTH
5.12.3 MAJOR PATENTS IN DIGITAL HEALTH MARKET
5.13 UNMET NEEDS AND END-USER EXPECTATIONS
5.13.1 UNMET NEEDS IN DIGITAL HEALTH MARKET
5.13.2 END-USER EXPECTATIONS
5.14 KEY CONFERENCES AND EVENTS
5.15 CASE STUDY ANALYSIS
5.15.1 CASE STUDY 1: CLINICAS DEL AZUCAR (CDA)
5.15.2 CASE STUDY 2: NOVA HOSPITAL & ENOVACOM
5.15.3 CASE STUDY 3: APPLE & NHS TEAMS
5.16 DIGITAL HEALTH MARKET: INVESTMENT LANDSCAPE AND FUNDING SCENARIO
5.17 TRADE ANALYSIS
5.17.1 TRADE ANALYSIS FOR DIGITAL HEALTH DEVICES (HSN CODE 8518)
5.17.2 TRADE ANALYSIS FOR DIGITAL HEALTH DEVICES (HSN CODE 9021)
5.17.3 TRADE ANALYSIS FOR DIGITAL HEALTH DEVICES (HSN CODE 9022)
5.17.4 TRADE ANALYSIS FOR DIGITAL HEALTH DEVICES (HSN CODE 9018)
5.18 DIGITAL HEALTH MARKET BUSINESS MODELS
5.18.1 SUBSCRIPTION-BASED MODELS
5.18.2 SOFTWARE AS A SERVICE (SAAS)/PLATFORM AS A SERVICE (PAAS)
5.18.3 FREEMIUM MODELS WITH TIERED ACCESS
5.18.4 OUTCOMES-BASED AND VALUE-BASED MODELS
5.19 IMPACT OF AI/GEN AI IN DIGITAL HEALTH MARKET
5.19.1 KEY USE CASES
5.19.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION
5.19.2.1 Artificial intelligence in public health
5.19.2.2 Artificial intelligence in digital health-issues and dimensions of ethical concerns
5.19.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
5.19.3.1 Telehealth and telemedicine
5.19.3.2 Wearable devices
5.19.3.3 Remote patient monitoring (RPM)
5.19.3.4 Mobile health (mHealth)
5.19.4 USER READINESS & IMPACT ASSESSMENT
5.19.4.1 User readiness
5.19.4.1.1 User A: Healthcare providers
5.19.4.1.2 User B: Healthcare payers
5.19.4.1.3 User C: Patients & consumers
5.19.4.1.4 User D: Pharmaceutical, biotech, and MedTech companies (including CROs)
5.19.4.1.5 User E: Other end users (academic institutes, research centers, government bodies)
5.19.4.2 Impact assessment
5.19.4.2.1 User A: Healthcare providers
5.19.4.2.1.1 Implementation
5.19.4.2.1.2 Impact
5.19.4.2.2 User B: Healthcare payers
5.19.4.2.2.1 Implementation
5.19.4.2.2.2 Impact
5.19.4.2.3 User C: Patients & consumers
5.19.4.2.3.1 Implementation
5.19.4.2.3.2 Impact
5.19.4.2.4 User D: Pharmaceutical, biotech, and MedTech companies (including CROs)
5.19.4.2.4.1 Implementation
5.19.4.2.4.2 Impact
5.19.4.2.5 User E: Other end users (academic institutes, research centers, government bodies)
5.19.4.2.5.1 Implementation
5.19.4.2.5.2 Impact
5.20 IMPACT OF 2025 US TARIFFS-DIGITAL HEALTH MARKET
5.20.1 INTRODUCTION
5.20.2 KEY TARIFF RATES
5.20.3 PRICE IMPACT ANALYSIS
5.20.4 IMPACT ON COUNTRIES/REGIONS
5.20.4.1 US
5.20.5 EUROPE
5.20.6 ASIA PACIFIC
5.20.7 IMPACT ON END-USE INDUSTRIES
5.20.7.1 Healthcare providers
5.20.7.2 Healthcare payers
5.20.7.3 Patients and consumers
5.20.7.4 Pharmaceutical, biotechnology, and MedTech companies
5.20.7.5 Other end users
5.21 REIMBURSEMENT ANALYSIS
5.22 RISK FACTORS AND MARKET ENTRY BARRIERS
5.23 FUTURE OUTLOOK AND DISRUPTION SCENARIOS

6 DIGITAL HEALTH MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 HARDWARE
6.2.1 SMART HARDWARE SOLUTIONS VITAL IN POWERING DIGITAL HEALTH
6.2.2 WEARABLES
6.2.2.1 Wearables to empower patients with real-time health monitoring
6.2.3 CONSUMER-GRADED WEARABLE HEALTHCARE DEVICES
6.2.3.1 Wearable healthcare devices to empower consumers to be proactive about their well-being
6.2.4 CLINICAL-GRADE WEARABLE HEALTHCARE DEVICES
6.2.4.1 Clinical-grade devices to allow remote care with continuous monitoring
6.2.5 IMPLANTABLE DEVICES
6.2.5.1 Real-time data transmission to healthcare providers for proactive intervention and personalized care
6.2.6 HANDHELD & PORTABLE DEVICES
6.2.6.1 Compact design and integration with mobile health applications to make them highly effective for use in remote care
6.2.7 STATIONARY DEVICES
6.2.7.1 Stationary devices to be upgraded with IoT integration, AI-driven analytics, and cloud-enabled interoperability
6.3 SOLUTIONS/APPLICATIONS
6.3.1 TELEHEALTHCARE/TELEMEDICINE
6.3.1.1 Demand to advance connected care via virtual health platforms
6.3.2 REMOTE PATIENT MONITORING
6.3.2.1 Expected to be more seamlessly integrated with telemedicine platforms, expanding their capabilities
6.3.3 VIRTUAL CARE & VIDEO CONSULTATION
6.3.3.1 Offering enhanced efficiency, accessibility, and accuracy in remote healthcare, assisting in triaging patients and automating documentation
6.3.4 VIRTUAL SITTING & NURSING PLATFORMS
6.3.4.1 Offering remote patient monitoring with bidirectional communication
6.4 MHEALTH APPS
6.4.1 TRANSFORMING CARE DELIVERY WITH MOBILE HEALTH SOLUTIONS
6.5 DIGITAL THERAPEUTICS
6.5.1 EMPOWERING HEALTH BY COMBINING REAL-TIME DATA COLLECTION, PATIENT ENGAGEMENT TOOLS, AND INTEGRATION WITH HEALTHCARE PROVIDERS' SYSTEMS
6.6 DIGITAL PHARMACY & MEDICATION ACCESS
6.6.1 ENHANCING MEDICATION ACCESS BY REACHING RURAL OR UNDERSERVED POPULATIONS, REDUCING TRAVEL AND WAIT TIMES, AND IMPROVING CONTINUITY OF CARE
6.7 DIGITAL DIAGNOSTICS & AT-HOME TESTING
6.7.1 MOSTLY USED IN GLUCOSE MONITORING AND OTHER INFECTIOUS DISEASE TESTS, CHOLESTEROL AND LIPID PANELS, GENETIC TESTING, AND HORMONE OR FERTILITY ASSESSMENTS
6.8 PATIENT PORTALS
6.8.1 PERSONALIZED HEALTH CONTENT, APPOINTMENT REMINDERS, AND SECURE MESSAGING AIM TO IMPROVE PATIENT ENGAGEMENT AND CARE COORDINATION
6.9 OTHER DIGITAL HEALTH SOLUTIONS/APPLICATIONS

7 DIGITAL HEALTH MARKET, BY DISEASE
7.1 INTRODUCTION
7.2 DIABETES
7.2.1 INTEGRATING AI IN DIGITAL HEALTH TO CATER TO DIABETIC PATIENTS
7.3 CARDIOLOGY
7.3.1 OFFERING EARLIER DETECTION, CONTINUOUS MONITORING, AND PERSONALIZED MANAGEMENT OF CARDIOVASCULAR CONDITIONS
7.4 MENTAL HEALTH & BEHAVIORAL HEALTH
7.4.1 IMPROVING ACCESSIBILITY TO MENTAL HEALTH SERVICES, ESPECIALLY IN UNDERSERVED REGIONS
7.5 RESPIRATORY DISORDERS
7.5.1 ENABLING REAL-TIME MONITORING OF LUNG FUNCTION, MEDICATION ADHERENCE, AND OXYGEN LEVELS
7.6 LIFESTYLE & WELLNESS IMPROVEMENT
7.6.1 EXPANDING ACCESS AND PERSONALIZING CARE IN MENTAL & BEHAVIORAL HEALTH THROUGH DIGITAL HEALTH
7.7 NEUROLOGY
7.7.1 ADVANCING NEUROLOGICAL CARE WITH DIGITAL HEALTH INNOVATIONS
7.8 MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT
7.8.1 ACCELERATING INNOVATION IN HANDHELD & PORTABLE DEVICES TO BOOST MARKET GROWTH
7.9 ONCOLOGY
7.9.1 ADOPTION OF AI IN REMOTE PATIENT MONITORING (RPM) TO LEAD TO ITS EMERGING AS PROMISING SOLUTION TO SUPPORT PERSONALIZED CARE
7.10 WOMEN'S HEALTH & REPRODUCTIVE HEALTH
7.10.1 ENHANCING PREVENTIVE CARE, EMPOWERING WOMEN WITH SELF-MANAGEMENT TOOLS, AND STRENGTHENING OUTCOMES IN REPRODUCTIVE AND MATERNAL HEALTH
7.11 OTHER DISEASES

8 DIGITAL HEALTH MARKET, BY USE CASE
8.1 INTRODUCTION
8.2 PREVENTIVE CARE & WELLNESS
8.2.1 DRIVING PROACTIVE HEALTH MANAGEMENT THROUGH DIGITAL INNOVATION
8.3 DIAGNOSIS
8.3.1 ADVANCING DIAGNOSIS THROUGH AI-POWERED SYMPTOM CHECKING AND EARLY DETECTION
8.4 TREATMENT
8.4.1 FEEDING REAL-TIME DATA TO HEALTHCARE PROVIDERS, ALLOWING TREATMENT ADJUSTMENTS AND PROACTIVE INTERVENTIONS
8.5 PATIENT MONITORING
8.5.1 SHIFT TOWARD PERSONALIZED, SCALABLE, AND PREVENTIVE CARE
8.6 REHABILITATION & RECOVERY
8.6.1 PARTICULARLY IMPACTFUL IN POST-SURGICAL CARE, NEUROLOGICAL REHABILITATION, STROKE RECOVERY, AND MUSCULOSKELETAL THERAPY
8.7 OTHER USE CASES

9 DIGITAL HEALTH MARKET, BY END USER
9.1 INTRODUCTION
9.2 HEALTHCARE PROVIDERS
9.2.1 HOSPITALS
9.2.1.1 Rise in demand for high-quality care and government support to encourage digital health adoption in hospitals
9.2.2 CLINICS & OTHER OUTPATIENT SETTINGS
9.2.2.1 Increase in demand for cost-effective care and postoperative monitoring to drive digital health adoption in outpatient settings
9.2.3 OTHER HEALTHCARE PROVIDERS
9.3 HEALTHCARE PAYERS
9.3.1 PUBLIC PAYERS
9.3.1.1 Driving population health and value-based care through digital innovation
9.3.2 PRIVATE PAYERS
9.3.2.1 Personalized benefit designs, value-based provider contracting, and delivering consumer-centric experiences
9.4 PATIENTS & CONSUMERS
9.4.1 AI AND WEARABLE DEVICES TO DRIVE GROWTH IN DIGITAL HEALTH FOR PERSONALIZED CARE AND ACCESSIBILITY
9.5 PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDTECH COMPANIES
9.5.1 PHARMACEUTICAL AND BIOTECH ADOPTION OF DIGITAL HEALTH TO ENHANCE DRUG DEVELOPMENT, PATIENT ENGAGEMENT, AND ADHERENCE
9.6 OTHER END USERS

10 DIGITAL HEALTH MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2 US
10.2.2.1 Integration of AI, data interoperability, and virtual-first care models to drive market
10.2.3 CANADA
10.2.3.1 Advancing health equity and access through digital infrastructure
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2 GERMANY
10.3.2.1 Innovation-focused policy framework and digital infrastructure expansion to support growth
10.3.3 UK
10.3.3.1 Increase in prevalence of chronic and lifestyle-related diseases and high penetration of wearables to drive market
10.3.4 FRANCE
10.3.4.1 Government support for e-Health to propel market
10.3.5 ITALY
10.3.5.1 Digital transformation and integrated care to support market growth
10.3.6 SPAIN
10.3.6.1 Health system modernization and data-driven care to enable digital health growth in Spain
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2 CHINA
10.4.2.1 High burden of chronic diseases to fuel market growth
10.4.3 JAPAN
10.4.3.1 Large geriatric population and strong push toward modernization to propel market
10.4.4 INDIA
10.4.4.1 Growing adoption of telemedicine and mounting pressure to reduce healthcare expenditure to drive market
10.4.5 AUSTRALIA
10.4.5.1 Telehealth and digital integration to drive growth in Australia's digital health market
10.4.6 SOUTH KOREA
10.4.6.1 AI, data ecosystems, and cross-sector synergy to power South Korea's digital health growth
10.4.7 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
10.5.2 BRAZIL
10.5.2.1 Government digitalization push and interoperability frameworks to catalyze market expansion
10.5.3 MEXICO
10.5.3.1 Government reforms, infrastructural expansion, and chronic disease burden to drive market
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
10.6.2 GCC
10.6.2.1 AI leadership, virtual infrastructure, and policy alignment to power digital health growth in GCC
10.6.2.2 Saudi Arabia
10.6.2.2.1 Rapid digital health transformation to propel market in Saudi Arabia
10.6.2.3 UAE
10.6.2.3.1 UAE emerges as regional pioneer in digital healthcare innovation
10.6.2.4 Rest of GCC
10.6.3 SOUTH AFRICA
10.6.3.1 Infrastructure expansion, youthful demographics, and innovation ecosystems to accelerate digital health growth
10.6.4 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DIGITAL HEALTH MARKET
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
11.4 MARKET SHARE ANALYSIS, 2024
11.5 BRAND/SOFTWARE COMPARISON
11.6 COMPANY VALUATION & FINANCIAL METRICS
11.6.1 FINANCIAL METRICS
11.6.2 COMPANY VALUATION
11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
11.7.1 STARS
11.7.2 EMERGING LEADERS
11.7.3 PERVASIVE PLAYERS
11.7.4 PARTICIPANTS
11.7.5 COMPANY FOOTPRINT
11.7.6 REGION FOOTPRINT
11.7.7 OFFERING FOOTPRINT
11.7.8 DISEASE FOOTPRINT
11.7.9 USE CASE FOOTPRINT
11.7.10 END USER FOOTPRINT
11.8 STARTUP/SME EVALUATION MATRIX, 2024
11.8.1 PROGRESSIVE COMPANIES
11.8.2 DYNAMIC COMPANIES
11.8.3 RESPONSIVE COMPANIES
11.8.4 STARTING BLOCKS
11.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
11.8.5.1 Detailed list of key startups/SMEs
11.8.5.2 Competitive benchmarking of startups/SMEs
11.9 COMPETITIVE SCENARIO AND TRENDS
11.9.1 PRODUCT LAUNCHES & APPROVALS
11.9.2 DEALS
11.9.3 OTHER DEVELOPMENTS

12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 MEDTRONIC
12.1.1.1 Business overview
12.1.1.2 Products offered
12.1.1.3 Recent developments
12.1.1.3.1 Product launches & approvals
12.1.1.3.2 Deals
12.1.1.3.3 Other developments
12.1.1.4 MnM view
12.1.1.4.1 Key strengths
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses and competitive threats
12.1.2 ABBOTT
12.1.2.1 Business overview
12.1.2.2 Products offered
12.1.2.3 Recent developments
12.1.2.3.1 Product launches & approvals
12.1.2.3.2 Deals
12.1.2.4 MnM view
12.1.2.4.1 Key strengths
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses and competitive threats
12.1.3 DEXCOM, INC.
12.1.3.1 Business overview
12.1.3.2 Products offered
12.1.3.3 Recent developments
12.1.3.3.1 Product launches & approvals
12.1.3.3.2 Deals
12.1.3.4 MnM view
12.1.3.4.1 Key strengths
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses and competitive threats
12.1.4 KONINKLIJKE PHILIPS N.V.
12.1.4.1 Business overview
12.1.4.2 Products offered
12.1.4.3 Recent developments
12.1.4.3.1 Product launches & approvals
12.1.4.3.2 Deals
12.1.4.3.3 Expansions
12.1.4.4 MnM view
12.1.4.4.1 Key strengths
12.1.4.4.2 Strategic choices
12.1.4.4.3 Weaknesses and competitive threats
12.1.5 FITBIT, INC. (GOOGLE)
12.1.5.1 Business overview
12.1.5.2 Products offered
12.1.5.3 Recent developments
12.1.5.3.1 Product launches & approvals
12.1.5.3.2 Deals
12.1.5.4 MnM view
12.1.5.4.1 Key strengths
12.1.5.4.2 Strategic choices
12.1.5.4.3 Weaknesses and competitive threats
12.1.6 OMRON HEALTHCARE, INC.
12.1.6.1 Business overview
12.1.6.2 Products offered
12.1.6.3 Recent developments
12.1.6.3.1 Product launches & approvals
12.1.6.3.2 Deals
12.1.7 APPLE, INC.
12.1.7.1 Business overview
12.1.7.2 Products offered
12.1.7.3 Recent developments
12.1.7.3.1 Product launches & approvals
12.1.7.3.2 Deals
12.1.8 BOSTON SCIENTIFIC CORPORATION
12.1.8.1 Business overview
12.1.8.2 Products offered
12.1.8.3 Recent developments
12.1.8.3.1 Product launches & approvals
12.1.8.3.2 Deals
12.1.9 MASIMO
12.1.9.1 Business overview
12.1.9.2 Products offered
12.1.9.3 Recent developments
12.1.9.3.1 Product launches & approvals
12.1.9.3.2 Deals
12.1.10 TELADOC HEALTH, INC.
12.1.10.1 Business overview
12.1.10.2 Products offered
12.1.10.3 Recent developments
12.1.10.3.1 Product launches & approvals
12.1.10.3.2 Deals
12.1.11 AMERICAN WELL
12.1.11.1 Business overview
12.1.11.2 Products offered
12.1.11.3 Recent developments
12.1.11.3.1 Product launches & approvals
12.1.11.3.2 Deals
12.1.11.3.3 Other developments
12.1.12 HIMS & HERS HEALTH, INC.
12.1.12.1 Business overview
12.1.12.2 Products offered
12.1.12.3 Recent developments
12.1.12.3.1 Product launches & approvals
12.1.12.3.2 Deals
12.1.13 HEADSPACE
12.1.13.1 Business overview
12.1.13.2 Products offered
12.1.13.3 Recent developments
12.1.13.3.1 Product launches & approvals
12.1.13.3.2 Deals
12.1.14 NOOM, INC.
12.1.14.1 Business overview
12.1.14.2 Products offered
12.1.14.3 Recent developments
12.1.14.3.1 Product launches & approvals
12.1.14.3.2 Deals
12.1.15 CEREBRAL INC.
12.1.15.1 Business overview
12.1.15.2 Products offered
12.1.15.3 Recent developments
12.1.15.3.1 Product launches & approvals
12.1.15.3.2 Deals
12.1.16 EPIC SYSTEMS CORPORATION
12.1.16.1 Business overview
12.1.16.2 Products offered
12.1.16.3 Recent developments
12.1.16.3.1 Product launches & approvals
12.1.16.3.2 Deals
12.1.17 OMADA HEALTH INC.
12.1.17.1 Business overview
12.1.17.2 Products offered
12.1.17.3 Recent developments
12.1.17.3.1 Product launches & approvals
12.1.17.3.2 Deals
12.1.18 ORACLE
12.1.18.1 Business overview
12.1.18.2 Products offered
12.1.18.3 Recent developments
12.1.18.3.1 Product launches & approvals
12.1.18.3.2 Deals
12.1.19 CLICK THERAPEUTICS, INC.
12.1.19.1 Business overview
12.1.19.2 Products offered
12.1.19.3 Recent developments
12.1.19.3.1 Product launches & approvals
12.1.19.3.2 Deals
12.1.20 WELLDOC, INC.
12.1.20.1 Business overview
12.1.20.2 Products offered
12.1.20.3 Recent developments
12.1.20.3.1 Product launches & approvals
12.1.20.3.2 Deals
12.1.21 EVERLYWELL
12.1.21.1 Business overview
12.1.21.2 Products offered
12.1.21.3 Recent developments
12.1.21.3.1 Product launches & approvals
12.1.21.3.2 Deals
12.2 OTHER PLAYERS
12.2.1 TRUDOC HEALTHCARE LLC
12.2.2 CARESIMPLE INC.
12.2.3 VIVALNK, INC.
12.2.4 BIOBEAT
12.2.5 VIRTUAL THERAPEUTICS CORP.

13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS